A Phase II Open Label, Multi-Center Study With AVR118 in Anorectic Patients With Recurrent or Advanced Malignancies

Inclusion Criteria:

* Histologically confirmed solid tumor cancer, leukemia, lymphoma, or multiple myeloma.
* Concurrent anti-cancer treatment, such as chemotherapy or radiation therapy is permitted except for neo-adjuvant or adjuvant programs.
* Between the ages of 18-85.
* Symptoms of recurrent or metastatic cancer in which anorexia is a predominant symptom, not necessarily associated with cachexia, and are not attributed to anemia, concomitant illnesses, or obstruction or loss of organ function.
* Karnofsky performance status of 40%
* Palliative Prognostic Score (PaP) of less than 6
* Patient is expected to be able to remain on a study protocol for two months.
* Pretreatment laboratory data within 7 days of enrollment:
* Hemoglobin \>8.5 g/dL , or on stable doses (hematocrit stable within 1 gram and dose stable for one month) of erythropoietin or similar medication.
* Absolute neutrophil count (ANC) 1,500/mm3.
* Platelets 50,000/mm3.
* Total bilirubin 2.0
* ALT and AST 2.5 times the ULN, or, if the patient has liver metastases, 5 times the ULN.
* Creatinine 1.5 mg/dL.
* Normal TSH
* Testosterone levels determined.
* Voluntary written informed consent before performance of any study-related procedure that is not part of normal medical care.
* Ability to self-administer subcutaneous medication if an assistant or nurse is not available, and to keep a compliance journal documenting injections at home.
* If on an antidepressant, the dose must have been stabilized for at least 30 days.
* Female patient is post-menopausal, surgically sterilized, or willing to use acceptable methods of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, or condom with spermicide, or abstinence) for the duration of the study.
* Male patient agrees to use an acceptable barrier method for contraception during the study

Exclusion Criteria:

* Patient has uncontrolled brain metastases or central nervous system disease.
* Patient has mechanical, non-reversible reason for not being able to eat, or have a potential for developing malignant bowel obstruction during the course of the induction phase of treatment, or patients requiring a PEG for obstruction.
* Patient has had any major surgery within four weeks of enrollment.
* Patient has an uncontrolled concomitant illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
* In the Investigator's opinion, potentially interfere with the completion of treatment according to this protocol.
* Female patient is pregnant or breast-feeding.